Despite the looming crises, Novartis will be shutting down antimicrobial research at its Novartis Institutes for Biomedical Research campus in Emeryville, California. There will be a loss of 140 jobs and the current projects will be put up for sale. This company was working on phase 2 clinical trial of LYS228 against complicated urinary tract infections and complicated intra-abdominal infections. The work on anti-dengue drugs and anti-malaria drugs (KAF156 and KAE609) were already in pipeline.
The US-based RAZOR (Randomised Open versus Robotic Cystectomy) trial revealed that robotic surgery is equally effective as traditional open surgery in order to treat bladder cancer. The study was funded by the National Cancer Institute and the discovery was published in the Lancet.
EchoNous announced that it has been granted FDA 510(k) clearance for its EchoNous Vein ultrasound device which could improve peripheral IV catheter placements. This system could provide real-time clear mages of superficial and deeper veins.
The U.S. Food and Drug Administration approved the first autonomous artificial intelligence diagnostic system, IDx-DR and the University of Iowa Healthcare has become the first healthcare organization to implement it.
Ibrutinib plus venetoclax (ABT-199) improves outcomes over standard therapy in patients with mantle-cell lymphoma (MCL) and a poor prognosis reports a new research in the New England Journal of Medicine.
An analysis of Bayer's XANTUS programme revealed the safety profile of the oral Factor Xa inhibitor Xarelto® (rivaroxaban) in clinical practice.
A new study by University of Alberta scientists found major potential in a fresh and potent class of chemical compounds for treating Zika virus and respiratory syncytial virus (RSV).
Autoimmune hepatitis is a chronic disease more commonly seen in females, where the human body’s immune system goes awry and attacks its healthy liver cells. This immune response causes hepatitis i.e. inflammation of the liver. If left untreated, this disease can result in complications such as cirrhosis of the liver and/or hepatic failure.
iBeat, a San Francisco-based start-up, launched a new pulse sensitive feature called iBeat Heart Watch which alerts healthcare professionals if it detects someone going into cardiac arrest.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.